128 related articles for article (PubMed ID: 8494699)
1. The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125.
Fisken J; Roulston JE; Sturgeon C; Badley RA; Jönrup I; Aspinall L; Leonard RC
Br J Cancer; 1993 May; 67(5):1065-70. PubMed ID: 8494699
[TBL] [Abstract][Full Text] [Related]
2. A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
Dhokia B; Canney PA; Pectasides D; Munro AJ; Moore M; Wilkinson PM; Self C; Epenetos AA
Br J Cancer; 1986 Dec; 54(6):891-5. PubMed ID: 3467785
[TBL] [Abstract][Full Text] [Related]
3. Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours.
Macdonald F; Bird R; Stokes H; Russell B; Crocker J
J Clin Pathol; 1988 Mar; 41(3):260-4. PubMed ID: 3162916
[TBL] [Abstract][Full Text] [Related]
4. The ovarian-carcinoma-associated sebaceous gland antigen is a member of the HMFG2-positive family of epithelial mucins.
de Kretser T
Tumour Biol; 1988; 9(2-3):154-64. PubMed ID: 2456600
[TBL] [Abstract][Full Text] [Related]
5. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
6. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
[TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor-associated antigen detected by the monoclonal antibody HMFG2 in human epithelial ovarian cancer.
Ward BG; Cruickshank DJ
Int J Cancer; 1987 Jan; 39(1):30-3. PubMed ID: 3793268
[TBL] [Abstract][Full Text] [Related]
9. Circulating mucins as tumor markers in ovarian cancer (review).
Devine PL; McGuckin MA; Ward BG
Anticancer Res; 1992; 12(3):709-17. PubMed ID: 1622128
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic ability of different human milk fat globule antigens in breast cancer.
Ceriani RL; Blank EW; Rosenbaum EH; Ben Zeev D; Lowitz RS; Johansen L; Trujillo T
Breast Cancer Res Treat; 1990 May; 15(3):161-74. PubMed ID: 2372570
[TBL] [Abstract][Full Text] [Related]
11. CA125 serum levels and secondary laparotomy in epithelial ovarian tumours.
Rome RM; Koh H; Fortune D; Cauchi M
Aust N Z J Obstet Gynaecol; 1987 May; 27(2):142-5. PubMed ID: 3479113
[TBL] [Abstract][Full Text] [Related]
12. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
McGuckin MA; Layton GT; Bailey MJ; Hurst T; Khoo SK; Ward BG
Gynecol Oncol; 1990 May; 37(2):165-71. PubMed ID: 1693126
[TBL] [Abstract][Full Text] [Related]
14. Expression of human milk fat globule antigens HMFG1 and HMFG2 on ovarian tumours and lung tumours.
Hay FG; Leonard RC
Dis Markers; 1988 Mar; 6(1):29-39. PubMed ID: 2456176
[TBL] [Abstract][Full Text] [Related]
15. Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2.
van Dam PA; Lowe DG; Watson JV; Jobling TW; Chard T; Shepherd JH
Cancer; 1991 Jul; 68(1):169-77. PubMed ID: 2049739
[TBL] [Abstract][Full Text] [Related]
16. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
17. Serum markers CASA and CA 15-3 in ovarian cancer: all MUC1 assays are not the same.
Devine PL; McGuckin MA; Quin RJ; Ward BG
Tumour Biol; 1994; 15(6):337-44. PubMed ID: 7997805
[TBL] [Abstract][Full Text] [Related]
18. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
19. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
20. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
